Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease

Transplantation

Volumn 90, Issue 9, 2010, Pages 1022-1029

  Ringden, Olle ^a   Hassan, Zuzana ^a   Karlsson, Helen ^a   Olsson, Richard ^a   Omazic, Brigitta ^a   Mattsson, Jonas ^a   Remberger, Mats ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Chemotherapy; Graft versushost disease; Granulocyte colony stimulating factor; Peripheral blood stem cells

Indexed keywords

ACICLOVIR; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LEUKEMIA; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG MONITORING; ENGRAFTMENT; FEMALE; GRAFT RECIPIENT; HAZARD RATIO; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HERPES SIMPLEX; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFANT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NEUTROPHIL; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REDUCED INTENSITY CONDITIONING; RELAPSE; RETROSPECTIVE STUDY; SCHOOL CHILD; SOLID TUMOR; THROMBOCYTE; THROMBOCYTE COUNT; WHOLE BODY RADIATION;

ABO BLOOD-GROUP SYSTEM; ACUTE DISEASE; ANIMALS; BACTEREMIA; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; LEUKOCYTE COUNT; MALE; MICE; PLATELET COUNT; PROBABILITY; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE DONORS;

EID: 78650269478     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181f585c7     Document Type: Article

References (43)

1. Appelbaum FR. Allogeneic marrow transplantation and the use of he-matopoietic growth factors. Stem Cells 1995; 13: 344.
2. Bishop MR, Tarantolo SR, Geller RB,etal.Arandomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96: 80.
3. Dallorso S,Rondelli R, Messina C, et al. Clinical benefits ofgranulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: Results of a prospective randomized trial. Haemato-logica 2002; 87: 1274.
4. Ernst P, Bacigalupo A, Ringden O, et al. A phase 3, randomized, placebo-controlled trial of filgrastim in patients with haematological malignancies undergoing matched-related allogeneic bone marrow transplantation. Arch Drug Inf 2008; 1: 89.
5. Locatelli F, Pession A, Zecca M, et al. Use of recombinant human gran-ulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia. Bone Marrow Transplant 1996; 17: 31.
6. Ozcan M, Ustun C, Akcaglayan E, et al. Recombinant human granulo-cyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoi-etic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 27: 499.
7. Ringden OT, Le Blanc K, Remberger M. Granulocyte and granulocyte- macrophage colony-stimulating factors in allografts: Uses, misuses, misconceptions, and future applications. Exp Hematol 2005; 33: 505.
8. Update ofrecommendations for the useof hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1996; 14: 1957.
9. Appelbaum FR. Use of granulocyte colony-stimulating factor following hematopoietic cell transplantation: Does haste make waste? J Clin Oncol 2004; 22: 390.
10. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after alloge-neic peripheral-blood transplantation compared with bone marrow in children and adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872.
11. Ho VT, Mirza NQ, Junco Dd D, et al. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic he-matopoietic stem cell transplantation: A meta-analysis. Bone Marrow Transplant 2003; 32: 771.
12. Khoury HJ, Loberiza FR Jr, Ringden O, et al. Impact of posttransplan-tation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006; 107: 1712.
13. Remberger M, Naseh N, Aschan J, et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant 2003; 32: 217.
14. Ringden O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416.
15. Morris ES, MacDonald KP, Kuns RD,et al. Inductionof natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation. Nat Med 2009; 15: 436.
16. Martin PJ. Choosing between GVHD and delayed engraftment. Nat Med 2009; 15: 363.
17. Ringden O, Paulin T, Lonnqvist B, et al. An analysis of factors predisposing to chronic graft-versus-host disease. Exp Hematol 1985; 13: 1062.
18. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98: 461.
19. Ringden O, Labopin M, Bacigalupo A, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblas-tic leukemia. J Clin Oncol 2002; 20: 4655.
20. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705.
21. Shimoda K, Okamura S, Inaba S, et al. Granulocyte colony-stimulating factor and platelet aggregation. Lancet 1993; 341: 633.
22. Minelli O, Falzetti F, Di Ianni M, et al. G-CSF-induced thrombocyto-penia in a healthy donor. Bone Marrow Transplant 2009; 43: 263.
23. Svahn BM, Ringden O, Remberger M. Treatment costs and survival in patients with grades III-IV acute graft-versus-host disease after allo-genic hematopoietic stem cell transplantation during three decades. Transplantation 2006; 81: 1600.
24. Shlomchik WD, Couzens MS, Tang CB,etal. Preventionof graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412.
25. Bishop MR, Tarantolo SR, Pavletic ZS,etal. Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation. J Clin Oncol 2000; 18: 2269.
26. Ringden O, Remberger M, Persson U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619.
27. Storb R, Deeg HJ, Fisher L, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: Long-term follow-up of three controlled trials. Blood 1988; 71: 293.
28. Hagglund H, Ringden O,Oman S, et al.A prospective randomized trial of filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 1999; 24: 831.
29. Bostrom L, Ringden O, Sundberg B, et al. Pretransplant herpesvirus serol-ogy and acute graft-versus-host disease. Transplantation 1988; 46: 548.
30. Bostrom L, Ringden O, Sundberg B, et al. Pretransplant herpes virus serology and chronic graft-versus-host disease. Bone Marrow Transplant 1989; 4: 547.
31. Ringden O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723.
32. Hentschke P, Barkholt L, Uzunel M, et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253.
33. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756.
34. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimer-ism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620.
35. Remberger M, Svahn BM, Mattsson J, et al. Dose study of thymoglobu-lin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004; 78: 122.
36. Schaffer M, Aldener-Cannava A, Remberger M, et al. Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens 2003; 62: 243.
37. Ringden O, Remberger M, Runde V, et al. Peripheral blood stem cell transplantation from unrelated donors: A comparison with marrow transplantation. Blood 1999; 94: 455.
38. Svahn BM, Remberger M, Myrback KE, et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood 2002; 100: 4317.
39. Lundgren G, Wilczek H, Lonnqvist B, et al. Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis Suppl 1985; 47: 137.
40. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977.
41. Sparrelid E, Hagglund H, Remberger M, et al. Risk factors for septice-mia during aplastic period after allogeneic bone marrow transplantation. Transplant Proc 1995; 27: 3530.
42. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
43. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1.